Tenosynovial Giant Cell Tumor

In this Healio interview, Sandra D’Angelo, MD, discussed two “interesting” studies for pigmented villonodular synovitis, or PVNS, presented at the Connective Tissue Oncology Society Annual Meeting.

Vimseltinib improved objective response rate compared with placebo for patients with tenosynovial giant cell tumor, according to topline data from the agent’s manufacturer.

A reduced dosage and updated regimen are now available for the oral small molecule pexidartinib in the treatment of adults with symptomatic tenosynovial giant cell tumor, according to a press release from the drug manufacturer.

The FDA announced today approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor that is linked to functional limitations or severe morbidity and does not improve with surgery.